NKCFO LLC’s Supernus Pharmaceuticals SUPN Stock Holding History

NKCFO LLC’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,500	Closed	-$264K	–	149
2020 Q4	$264K	Buy	+10,500	New	+$226K	0.1%	49

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

ACM

Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

NKCFO LLC's SUPN Position: Q1 2021 in Review

NKCFO LLC sold out of Supernus Pharmaceuticals (SUPN) in Q1 2021, closing a stake of 10,500 shares — an estimated $264K sold.

NKCFO LLC first reported a position in SUPN in Q4 2020 and held it in 1 quarter. The position peaked at $264K in Q4 2020. 224 funds tracked by Wall St. Rank hold SUPN as of Q1 2021.

NKCFO LLC reported no remaining Supernus Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
NKCFO LLC sold 10,500 Supernus Pharmaceuticals shares in Q1 2021, an estimated $264K.
NKCFO LLC first reported a position in Supernus Pharmaceuticals in Q4 2020 and held it in 1 quarter.
NKCFO LLC's Supernus Pharmaceuticals position peaked at $264K in Q4 2020.
224 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2021.

Based on NKCFO LLC's 13F filing for Q1 2021, filed 3 May 2021.